LONDON – Ablynx NV improved the prospect of triggering a phase III opt-in and €75 million (US$83.1 million) option payment from Abbvie Inc., turning in positive top-line results in a phase IIb combination study of its anti-interleukin-6R (IL-6R) nanobody, vobarilizumab (ALX-0061), in the treatment of rheumatoid arthritis.